By Kim Tae-gyu Staff Reporter A team of international scientists has found through rodent experiments that embryonic stem cells can help control psychological disorders, such as depression.
Drs. Miles Cunningham and Kim Kwang-soo at Harvard Medical School and Prof. Kim Dong-wook at Yonsei University recently announced their collaborative findings at the 2006 Seoul Symposium on Stem Cell Research at Yonsei University.
``Our team differentiated embryonic stem cells into nerve cells generating dopamine and serotonin while Dr. Cunningham devised a model of psychiatric disease for applying our technology, engrafting and evaluating approximately 80 animals,’’ Kim said.
``Then, the animals behaved as if they had taken anti-depressant medication. The tests demonstrate embryonic stem cells may be used to treat mental diseases in the future,’’ Kim said.
Dopamine and serotonin are well-known neurotransmitters, or the chemicals playing a key role in relaying, amplifying and modulating electrical signals between brain cells.
Researchers found low levels of the such neurotransmitters are associated with several disorders, notably Parkinson’s disease, depression and anxiety, to name a few.
``Our next goal is to inject dopaminergic and serotonergic neurons into rodent brains separately to watch how they work in the central nervous system,’’ Kim said.
``The experiments are progress. But we are still at the initial stage and it will take a long time to apply them to a human being,’’ Kim said.
The team will disclose these results soon to a well-known medical journal.
The Seoul Symposium on Stem Cell Research is an annual event, which first took place in 2003 hosted by the stem cell research center at Korea’s Ministry of Science and Technology.
posted
MedSpas Appoints Solana's CEO John Buckingham to Advisory Board to Implement Acquisition Growth Strategy Market Wire - October 19, 2006 9:30 AM ET
MedSpas of America, Inc. (PINKSHEETS: MDSP), www.medspasofamerica.com, today announces that John Buckingham, Co-founder and Chief Executive Officer of Solana MedSpas, has joined the company's Advisory Board and will immediately begin rolling out the company's acquisition growth strategy to take advantage of the enormous demand in this industry. John Buckingham is the Co-founder and Chief Executive Officer of Solana MedSpas, www.solanamedspas.com,the nation's foremost medical spa developer. Mr. Buckingham is a founding board member of the International Medical Spa Association, www.medicalspaassociation.org, and serves as their Vice President of Corporate Affairs. He has co-created, with the University of California, Irvine, a new Spa and Hospitality Management Certificate Program. As a pioneer in the Medical Spa and healthcare industry, Mr. Buckingham is a much sought after speaker and expert. Mr. Buckingham was recently featured in the Wall Street Journal, Fortune, New York Newsday, The Miami Herald, The Dallas Morning News, The Orange County Business Journal, Plastic Surgery News, American Spa Medical Spa Report, and MEDIcalSPAS The Healthy-Aging Business Review. Mr. Buckingham holds a Bachelor of Science in Pharmacy with distinction from Purdue University and a Master's in Business Administration from Harvard Business School.
About MedSpas of America, Inc.
MedSpas of America, Inc., www.medspasofamerica.com, is dedicated to the development and operations of MedSpas throughout the United States under the brand name of Virtuoso Medical Spas. Virtuoso was founded by leading practitioners and accomplished executives in response to the growing marketplace demand for technology-based medical spa facilities that are committed to professional skin care.
It is straightforward to see that when useful stem cells can be generated easily, then research, the technology base, and the development of therapies will progress more rapidly. I suspect that, from the perspective of twenty years hence, the real value of adult stem cells and first generation autologous stem cell therapies will be in the technologies, infrastructure and experience gained from the exercise - especially experience in controlling the differentiation of stem cells into the desired type.
With this in mind, it has been educational to watch just how much scientists have been doing with stem cells taken from skin - from hair follicles, to be precise - over the past few years. My attention was drawn today to a proof of concept work in differentiating skin stem cells:
Nestin+ hair follicle-associated cells of murine skin can be isolated and differentiated in vitro into neuronal and glial cells. Therefore, we have asked whether human skin also contains nestin+ cells, and whether these can be differentiated in vitro into neuronal and/or glial cell populations. In this methodological pilot study, we show that both are indeed the case - employing purposely only very simple techniques for isolating, propagating, and differentiating nestin+ cells from normal human scalp skin
Therefore, human scalp skin can serve as a highly accessible, abundant, and convenient source for autologous adult stem cell-like cells that offer themselves to be exploited for neuroregenerative medicine purposes.
The near future of regenerative medicine is bright indeed. Enough funding and ingenuity are present in the field to see through a revolution in how we view and treat degenerative conditions. __________________
posted
sooner or later when it all hits the fan and theres no more embryonic stem cell companies and they all moved towards the read deal os adult stem cells then thats when the big money will be rolling in for many of these companies
from the other board
came across this article in the Palm Beach Post (my local newspaper) and since the county is trying to build a very large medical R&D facility with Scripps as the primary resident stem cells are a hot topic.
Respect life activists debate stem cell research ethics By Alexia Campbell
Palm Beach Post Staff Writer
Sunday, October 15, 2006
palmbeachgardens — Whether life needs to be destroyed to save more lives was one of the hotly debated topics that brought hundreds of pro-life activists and Catholics from all over the state to the Marriott Hotel this weekend.
The Catholic Diocese of Palm Beach is hosting the Florida Respect for Life Conference, which highlighted, among other issues, the ethics and science behind embryonic stem cell research.
The Rev. Tadeusz Pacholczyk of The National Catholic Bioethics Center warned people about the danger he sees in believing that human embryo cells are essential in curing diseases such as leukemia and diabetes. Government officials and the media, he said, frequently overlook the fact that using adult cells instead of embryonic cells is not only more effective but also doesn't require what he views as terminating a life.
"What is happening is people are getting the impression that all of the benefits in the hospital for human patients are coming from embryonic stem cells, and yet no human has been treated of any disease using stem cells from embryos," said Pacholczyk, who received a Ph.D. in neuroscience from Yale University. "Yet, thousands of people have been treated using the adult and umbilical stem cells."
Stem cell therapy relies on new techniques that replace diseased cells with healthy ones. Scientists from biotech firms such as the Genesis Genetics Institute in Detroit say that although embryonic stem cell research has not cured these diseases, it has made significant advances in regenerative medicine.
Testing for inherited forms of deafness, skin conditions or for a predisposition to arthritis and obesity are among the technology's breakthroughs.
But Pacholczyk said one of the reasons embryonic cells get so much attention is because of their potential for profit.
Whether created in petri dishes or derived from aborted fetuses, isolated embryonic stem cell lines can be patented and sold. But removing cells from an adult's hip region to treat his own heart after a heart attack does not generate as much private revenue, he said. Proposals to allow state and federal funds to promote embryonic cell research is wasteful and wrong, he said.
"They are using taxpayer money for something that is objectionable to a large portion of population and is a violation of the Declaration of Independence that all are created equal," he added.
Jeannette Mikelonis was among the estimated 450 people at the three-day conference, which ends today. Other topics covered included doctor-assisted suicide and Catholic palliative health care. Mikelonis said she drove from Sebring and was glad to hear Pacholczyk talk about adult stem cells.
"I had leukemia and none of my siblings matched me, so they took cells out of my bone marrow and three months later I was fine," said the 73-year-old. "It's good that he explained all these things, because unless you go through this, it's hard to understand."
Pacholczyk also mentioned a petition circulating that would allow residents to vote on an amendment to the state constitution prohibiting government spending on "experimentation that involves the destruction of a live human embryo."
Don Kazimir, director of the five-county Palm Beach Diocese's Respect Life Office, said Palm Beach County is an ideal place for the conference because it's the site for The Scripps Research Institute.
"We are here to inspire people to do more to stop these sort of things," Kazimir said. "If Scripps decides to work with embryonic stem cells, people will be demonstrating. There will be tons of people outside each of these businesses protesting it."
Today’s Price Performance as of 9:38am EDT, 10/25/2006 Option Chains Margin Requirements Interactive Chart
Loading Chart1 Day | 5 Day | 6 Mo | 1 Yr | 3 Yr | 5 Yr $0.0402 Last Price 0.0048 -10.67% Today’s Change $0.04 Today’s Open 50,390 Above Avg. Today’s Volume
-------------------- All I say is IMHO.
I like these calm little moments before the storm... Reminds me of Bethoven Posts: 3255 | From: Orlando, FL | Registered: Mar 2006
| IP: Logged |
The promise of adult stem cell therapies is an exciting one! One of the most exciting new medical technologies that may hold the key to fighting aging and disease could lie within our own stem cells and their ability to repopulate and replace cells that have been damaged by the aging process, disease or injury. The Stem Cell Research Foundation aptly refers to stem cell therapy as a “revolution in medicine”. Medical professionals see preserved stem cells as a new source of cells that can be used in the rebuilding and repair of the body’s tissues, organs, even the immune system. In fact, “stem cell therapy techniques are being applied experimentally to a wide range of human disorders, including many types of cancer, neurological diseases such as Parkinson’s disease, ALS (Lou Gehrig’s disease), spinal cord injuries, heart disease, liver disease, muscular dystrophy, stroke and diabetes. Even blinding diseases of the retina may someday be cured by replacing dead retinal cells with new ones!” Consider this…the stem cells that you choose to preserve today, could be used to return the gift of life and health tomorrow!
What You Should Know About Stem Cell Therapies
Although much of the work in the field of stem cell therapy is still largely experimental, applications of this technology have been in use for years. For example, a bone marrow transplant is the most common type of stem cell therapy, one in which the stem cells in a donor’s marrow are used to replace the blood cells of the victims of leukemia and other cancers. Cell therapy is also being tested to graft new skin cells for burn victims and to regenerate corneas for those that are sight-impaired. In a recent advance, pancreatic cells were implanted into the body of a diabetic and began producing insulin!
posted
I just have a feeling that the company is now putting together an information package to cover a lot of questions and also to announce the opening of the new website and even more locations.The e-mail I got from Life Stem yesterday reinforced this feeling.
posted
the movement in stem cells is just beginnning and this company is looking very solid in delivering cellular therepeutics in the future.
clbe is quietly emerging onto the stem cell and life science scene as the business model unfolds and evolves. I read through the last 10q again and thought i would point out a couple of highlights. if you are long or considering buying into a significant position here are some points to consider.
LifeStem has initially concentrated on medspa locations in Southern California. At a recent meeting of all of the current Solana Medspas, a large number of the medspas outside of California expressed enthusiasm as to being able to carry LifeStem's service outside of California and LifeStem is working to make that happen more rapidly than originally anticipated. As such, the Stem Cell MicroBank Service will be initially rolled out in California and then quickly move to other states such as Florida, New York and North Carolina. LifeStem is projecting $3,858,000 in revenues in the first twelve months of operation and $26,275,000 during the second twelve months of operation. :Booyah: :Booyah: :Booyah:
The Company realized Net Income for the six months ended June 30, 2006 of $13,363 as compared to a net loss of $2,220,898 for the same period in 2005, due primarily to an unrealized gain on adjustment of derivative and warrant liability to fair value of underlying securities relating to the convertible notes it obtained in 2005. For the three months ended June 30, 2006, net income loss was $1,164,176, as compared to a loss of $1,950,448 for the same period in 2005. Operationally, the Company believes that increased revenues and profitability generated by KD Medical, continued growth and new profitability of Molecula, along with the Stem Cell Microbank(TM) sales from LifeStem will result in a net profit for 2006.
In addition to advancing its unique business model for stem cell banking and the provision of purified stem cells to researchers, CalbaTech has filed two patent application for intellectual property relating to (1) a device for the efficient and effective delivery of stem cells to diseased or dead areas of the heart (2) a method of collecting and storing two different types of stem cells in micro quantities for autologous use.
and lastly..an overlooked favorite of mine.....
The device is intended to be compatible with endoscopes from various manufactures.. LifeStem is currently seeking a collaborative partner to develop a prototype of the device and is discussing this possibility with several of the nation's leading medical device manufacturers.
clbe is slowly and quietly putting the pieces together...2-10years is what Van Tassel said in that interview.....imo if management stays on course we will see dollars and beyond here....easlily!
$26,275,000 during the second twelve months of operation. :LOL:
posted
CalbaTech's Web Site Features New Interview with Chief Medical Officer Dr. Jason Tassel, M.D., from CalbaTech's Subsidiary, LifeStem, Inc.
Dr. Jason Tassel, M.D., Chief Medical Officer, LifeStem, Inc., the wholly-owned subsidiary of CalbaTech, was recently interviewed about LifeStem's progress and the importance of banking stem cells on Los Angeles radio station WKNX-1070. A link to the interview is now available at CalbaTech's web site: http://www.calbatech.com .
It will keep you updated about the proprietary method of stem cell banking that LifeStem is bringing to the marketplace; about why stem cells should be banked now, and about the promise of adult stem cell therapies. It also answers frequently asked questions about the storage process.
And if you've in a surfing mood, visit http://www.solanamedspas.com to learn more about LifeStem's Stem Cell MicroBank(TM) Service offered through Solana MedSpas' national network.
posted
Pumping over here now Quest!!!! Your a joke!
-------------------- 'The rewards for those that persevere, far exceed the pain that must proceed the victory!' Posts: 399 | From: leeds, england | Registered: Jul 2006
| IP: Logged |
quote:Originally posted by renrob05: [QUOTE]Originally posted by fhalyesss: [qb] Pumping over here now Quest!!!! Your a joke!
Quest really believes in this company.
Thats why he is pumping it Buddy!!!
-------------------- 'The rewards for those that persevere, far exceed the pain that must proceed the victory!' Posts: 399 | From: leeds, england | Registered: Jul 2006
| IP: Logged |
posted
IMO Quest is one of the better posters on Allstocks, and I made money twice on his pick AMEP.
I haven't done any DD on this stock, but I do know that Quest always includes DD with his post and doesn't simply shout "to the moon" and "this one is going to 10$ next week" like so many of the real "pumpers" around here.
-------------------- One is never completely useless. One can always serve as a bad example. Posts: 2430 | From: CA | Registered: Jun 2005
| IP: Logged |
posted
CalbaTech's Web Site Features New Interview with Chief Medical Officer Dr. Jason Tassel, M.D., from CalbaTech's Subsidiary, LifeStem, Inc.
Dr. Jason Tassel, M.D., Chief Medical Officer, LifeStem, Inc., the wholly-owned subsidiary of CalbaTech, was recently interviewed about LifeStem's progress and the importance of banking stem cells on Los Angeles radio station WKNX-1070. A link to the interview is now available at CalbaTech's web site: http://www.calbatech.com .
It will keep you updated about the proprietary method of stem cell banking that LifeStem is bringing to the marketplace; about why stem cells should be banked now, and about the promise of adult stem cell therapies. It also answers frequently asked questions about the storage process.
And if you've in a surfing mood, visit http://www.solanamedspas.com to learn more about LifeStem's Stem Cell MicroBank(TM) Service offered through Solana MedSpas' national network.
Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Dr. Van Tassel was accepted into the well-known Department of Otolaryngology, Head and Neck Surgery Residency program at the University of Arkansas for Medical Sciences, headed by world famous Dr. James Suen. ... Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery.
Prior to beginning his practice of medicine in Los Angeles, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays, an area of specific interest to CalbaTech. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Department of Neurosciences at San Diego State under Dr. Gregory Harris, Ph.D., also an area of significant potential interest for CalbaTech. ... Dr. Van Tassel is also the Chief Medical Officer for CalbaTech's subsidiary, LifeStem.
(b) Compliance with Section 16(a) of the Exchange Act.
In addition to his undergraduate studies, Dr. Van Tassel worked as a research assistant at Hybritech Incorporated investigating the optimization of manufacturing processes related to monoclonal antibody test assays. During his undergraduate studies, he also worked as a physics instructor for the Healthcare Career Opportunity Program to provide educational assistance to underprivileged students interested in pursuing careers in medicine.
Dr. Van Tassel attended the prestigious Georgetown University School of Medicine located in Washington DC. He graduated with Honors in 1997 being admitted to the Alpha Omega Alpha Honor Society.
Dr. Van Tassel was accepted into the prestigious Department of Otolaryngology, Head and Neck Surgery Residency program at the University of Arkansas for Medical Sciences headed by world renowned Dr. James Suen. ... Dr. Van Tassel was a staff member of Kaiser Permanente Medical Group, Anaheim where he further developed his expertise in the specialty as the most productive individual Otolaryngology, Head and Neck Surgeon in the Department.
Along with his expertise in treating Ear, Nose and Throat disorders, Dr. Van Tassel has special expertise in Traditional, Laser Treatment, and Augmentation Fillers Applications for Facial Enhancement and Rejuvenation. He is excited to offer these highly skilled services to the patients of Pacific Specialists.
Dr. Van Tassel is a member of the Medical Staffs of Saint John,s Health Center, Santa Monica-UCLA Medical Center, Daniel Freedman Marina Medical Center and Brotman Medical Center. He is available for consultations at these medical centers and at Pacific Specialists Brentwood and Marina del Rey physician offices.
Dr. Van Tassel is married to Jenifer Aronowitz PhD, and resides in West Los Angeles.
Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Dr. Van Tassel was accepted into the well-known Department of Otolaryngology, Head and Neck Surgery Residency program at the University of Arkansas for Medical Sciences, headed by world famous Dr. James Suen. ... Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery.
Prior to beginning his practice of medicine in Los Angeles, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays, an area of specific interest to CalbaTech. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Department of Neurosciences at San Diego State under Dr. Gregory Harris, Ph.D., also an area of significant potential interest for CalbaTech.
posted
BIG TIME volume rolling in. Almost 2x 5 day volume average <10 in to the day. Up 6%.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
lots of stems getting decerved attention finally including STEM and ACTC but CLBE is so undervalued its ridiculus.....like to see us bust the .06 hump today! This should be over a dime anyhow!
posted
Mo. stem cell vote aids biotechs Price up for Stemcells, Geron ahead of initiative, which squeaked to approval. By Aaron Smith, CNNMoney.com staff writer November 8 2006: 3:04 AM EST
NEW YORK (CNNMoney.com) -- The results of Missouri's referendum on stem cell research Tuesday could impact several biotechs specializing in that line of work.
The big threat to big pharma In fact, they already have. Judging from recent stock activity, investors seemed to think that voters would approve Amendment 2, which would ensure that any federally approved stem cell research and treatments would be available in Missouri.
It looks like they were right - barely. The initiative carried by about a 51-49 margin as of 3 a.m. ET.
"This is delineating the first real battle ground for stem cell research in America today," said Stephen Brozak, analyst for WBB Securities.
Stock prices for two biotechs specializing in embryonic stem cell research - Stemcells Inc (Charts). and Geron Corp. (Charts) - have risen since the beginning of last week, when the political advertising and rhetoric really ramped up. Stemcells stock has risen about 4 percent in the last week or so while Geron is has surged nearly 40 percent since the beginning of October.
"All boats are lifted by this type of a rising tide," said Brozak, noting that biotechs involved in the less controversial adult stem cell research are also being affected by anticipation of the Amendment 2 vote.
Thermogenesis Corp. (up $0.03 to $4.38, Charts) has jumped about 6 percent in the last seven sessions and Osiris Therapeutics (down $0.04 to $16.00, Charts) is up about 4 percent, while trading has been flat for Cytori Therapeutics (up $0.04 to $4.14, Charts). These adult stem cell companies harvest stem cells from donated human tissue instead of embryos.
As always with biotechs, beware that investing in these companies is risky. Brozak said that a negative vote on the referendum could have a big negative impact on the biotechs.
The Missouri referendum has gotten a lot of nationwide attention, aided in no small part by Michael J. Fox, an actor with Parkinson's disease who appeared in television ads supporting stem cell research. Proponents of stem cell research point to its possible but so far unproven benefits, such as curing Parkinson's and other debilitating diseases, and repairing spinal and cerebral damage.
President Bush has spoken out against embryonic stem cell research for the same reason that he opposes abortion. Earlier this year, Bush vetoed a bill that would loosen federal restriction for stem cell research.
posted
The technology is real. Let's see if this performs as it should...especially with the new contract to Solana Medspa.
Heart attack victims to be given own stem cells By Nigel Hawkes
A revolutionary treatment is giving patients hope of making a much more rapid recovery
::nobreak::Click here to see how stem cells can mend broken hearts
Heart attack victims will be given a revolutionary new treatment involving an injection of their own stem cells to repair the organ damage that they have suffered.
Groundbreaking clinical trials are to start at two London hospitals into the use of the therapy, which is carried out within hours of a cardiac arrest.
Patients will be given injections of stem cells extracted from bone marrow taken from the hip to delay or prevent the onset of heart failure.
Animal experiments and some clinical studies in Europe have suggested that the treatment will work, but the British research, to be carried out at University College Hospital (UCH) and Bart’s and the London, will be the first double-blind clinical trial designed to prove it.
Stem cells found in the bone marrow have the capacity to develop into a wide variety of cells. In this case, it is hoped that they will turn into muscle cells, repairing the damage of the heart attack or preventing it from occurring.
Each year about 87,000 Britons suffer heart attacks — the equivalent to one every two minutes. Heart disease, leading to heart failure, claims 108,000 lives in the UK annually. Fewer people have been dying during the acute phase of a heart attack over the past decade, but survivors often go on to die from long-term effects, including heart failure.
John Martin, a cardiologist with the British Heart Foundation, based at UCH, said that there were many potential benefits to the new treatment, which could not only save lives, but also carried no added costs.
“There have been a couple of clinical trials in Germany to demonstrate that the technique is safe. In these trials, the bone marrow cells were given late, some time after the heart attack, in order to repair the muscle,” Professor Martin said.
“We believe that if we give it immediately, it can prevent damage. We will show whether it works in acute heart attack — and the treatment will involve no extra stay in hospital and virtually no extra cost.”
When patients are admitted to hospital after a heart attack, they are usually treated with balloon angioplasty, in which a catheter is inserted through the groin and into the blocked coronary artery. A balloon is then inflated to reopen the artery. Professor Martin said that the technique had led to significant increases in survival and decreases in damage to heart muscle.
The trial will test the effect of adding a further stage to the process. Bone marrow will be extracted from the patient’s hip bone, treated to separate out the right type of cells, and injected into the heart through the angioplasty catheter.
The plan is to treat 100 patients at the London Chest Hospital, part of Bart’s, and the London Heart Hospital, which is attached to UCH.
Half will be given the stem cell treatment, and half the identical treatment, but using a placebo. Neither doctor nor patient will know which is being given.
After two years each patient’s condition will be assessed using MRI scans, to see how well the heart is pumping, and there will be quality-of-life assessments to determine whether the patients given the bone marrow cells are fitter than the controls.
“There is good animal evidence in rats and mice that it will work,” Professor Martin said. “There are no drugs involved, and nothing to patent, so if the treatment works it will be available to all who can benefit, without extra cost.”
The trial has been backed by the UK Stem Cell Foundation, which helps pioneering stem cell projects, and is supported financially by William Bollinger and his wife, Judith, both successful bankers, and the London Development Agency.
David Macauley, chief executive of the UK Stem Cell Foundation, said: “It’s an interesting approach, and the animal data says we’re going to see some benefits. Heart disease is still the biggest killer. It killed 108,000 people last year, and there’s a heart attack every two minutes. There is no quality treatment available for the damage done by a heart attack.
“We want to see people getting back to work, or back to the golf course. We’re looking for very, very clear benefits.”
Anthony Mathur, senior lecturer and consultant cardiologist at Bart’s, said: “If we can demonstrate improvement in the quality of life of patients, then this will be a significant step forward in the treatment of heart disease.
“Because the stem cells are taken from the patient, there are minimal ethical issues surrounding this procedure. There is also less likelihood of rejection complications.”
The trial was welcomed by Professor Peter Weissberg, medical director of the British Heart Foundation, who said: “In the future, stem cells could herald a new frontier for heart patients. We welcome research that helps us understand the potential role stem cells may yet play in treating heart disease.”
Posts: 60 | Registered: Nov 2005
| IP: Logged |
posted
CalbaTech Announces Increase in Revenue for Nine Months; LifeStem Continuing to Enroll New Medspas to Sell Its Stem Cell MicroBank(TM) Service
- $3.58 Million Projection for Revenues for First Year Banking Services -
IRVINE, Calif., Nov 15, 2006 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, today announced that revenues for the first nine months ended September 30, 2006 totaled $977,444, up three percent compared to the same period in 2005. Net income for the first nine months of 2006 totaled $629,822, or $0.01 per share, compared to a loss in 2005. The net income reported is because of the unrealized gain on adjustment of derivative and warrant liabilities to fair value of the underlying securities relating to the convertible notes CalbaTech obtained in 2005. CalbaTech posted a gross profit of $579,443 for the nine month period, compared to a gross profit of $449,330 for the first nine months of 2005.
The Company also announced a significant decrease in operating expenses, from $1.72 million for the nine months ended September 30, 2005 to $1.33 million for the same period in the current year. "We continue to be successful in cutting costs and increasing profitability," said James DeOlden, CEO.
In its Form 10-QSB filing, CalbaTech said its wholly-owned subsidiary, LifeStem, (www.life-stem.com) has moved ahead with its roll-out of the Stem Cell MicroBank(TM) Service, collecting adult stem cells for possible future needs, through the Solana Medspas network. LifeStem has begun marketing its service, providing marketing materials to the individual medspas, and has begun providing training to the medspa personnel. In a major positive development, Solana Medspas has entered into a letter of intent with a partner to open 4,000 additional medspas throughout the country within the next four years, all of which potentially would carry LifeStem's banking services.
"LifeStem is conservatively projecting $3.858 million in revenues in the first 12 months of operation and $26.3 million during its second 12 months," Mr. DeOlden said. "While we have not processed any clients yet, it is not because of lack of interest. We have received requests for subscription packets, have begun hosting seminars to potential clients, and our Chief Medical Officer, Dr. Jason Van Tassel, M.D. appeared on the radio and the Internet to discuss our service to a significant listening audience. Some of the regulatory, logistical and training issues have taken longer than anticipated, but this is to be expected in a new breakthrough service such as ours."
Mr. DeOlden continued, "The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis could revolutionize the practice of medicine. The market for stem cell technology has been estimated to grow to $30 billion by the year 2010."
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
I feel more confident in CLBE now then I ever have and after digging in some more last night I see this 10-Q is by far the best they ever had so far and get clear insight to the direction of where this company is heading!!! This is the only OTCbb I have ever seen that barely did not increase the OS over 9 months....with the now new partnerships with Medspa they are looking at 4000 new locations over the next few years!!! That’s insane what kind of revs that can generate!!! Its no wonder in the recent interview they are projecting $100 million dollars a year and that’s conservative!!! As stated before I believe the target timing for CLBE to reach massive highs breaking the buck mark will be 12 to 18 months from last March 2006 but that target may get shorter now due to recent developments and any announcement at all of the 3 patents approval and this will go insane quick!! I urge all of you to take the time and read the financials from top to bottom!
CalbaTech Announces Increase in Revenue for Nine Months; LifeStem Continuing to Enroll New Medspas to Sell Its Stem Cell MicroBank(TM) Service Nov 14 2006, 11:00 PM EST
PRNEWSWIRE
IRVINE, Calif., Nov. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, today announced that revenues for the first nine months ended September 30, 2006 totaled $977,444, up three percent compared to the same period in 2005.
Net income for the first nine months of 2006 totaled $629,822, or $0.01 per share, compared to a loss in 2005. The net income reported is because of the unrealized gain on adjustment of derivative and warrant liabilities to fair value of the underlying securities relating to the convertible notes CalbaTech obtained in 2005. CalbaTech posted a gross profit of $579,443 for the nine month period, compared to a gross profit of $449,330 for the first nine months of 2005.
The Company also announced a significant decrease in operating expenses, from $1.72 million for the nine months ended September 30, 2005 to $1.33 million for the same period in the current year. "We continue to be successful in cutting costs and increasing profitability," said James DeOlden, CEO.
In its Form 10-QSB filing, CalbaTech said its wholly-owned subsidiary, LifeStem, (www.life-stem.com) has moved ahead with its roll-out of the Stem Cell MicroBank(TM) Service, collecting adult stem cells for possible future needs, through the Solana Medspas network. LifeStem has begun marketing its service, providing marketing materials to the individual medspas, and has begun providing training to the medspa personnel. In a major positive development, Solana Medspas has entered into a letter of intent with a partner to open 4,000 additional medspas throughout the country within the next four years, all of which potentially would carry LifeStem's banking services.
"LifeStem is conservatively projecting $3.858 million in revenues in the first 12 months of operation and $26.3 million during its second 12 months," Mr. DeOlden said. "While we have not processed any clients yet, it is not because of lack of interest. We have received requests for subscription packets, have begun hosting seminars to potential clients, and our Chief Medical Officer, Dr. Jason Van Tassel, M.D. appeared on the radio and the Internet to discuss our service to a significant listening audience. Some of the regulatory, logistical and training issues have taken longer than anticipated, but this is to be expected in a new breakthrough service such as ours."
Mr. DeOlden continued, "The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis could revolutionize the practice of medicine. The market for stem cell technology has been estimated to grow to $30 billion by the year 2010." __________________
Finally, in this quarter, LifeStem has begun its roll-out of its services to medspas through the Solana Medspa network. As part of the roll-out, LifeStem has provided marketing materials, training materials and begun providing training to the medspas. The relationship with Solana Medspas is an important relationship as the LifeStem services fit the medspa demographic very well. Additionally, Solana Medspas has entered into a contract with another partner whereby their projections are of opening 4,000 medspas throughout the country within the next four years. Our agreement with Solana Medspas provides for our Stem Cell Microbank Service to be potentially carried in every medspa that is opened by Solana Medspas, subject to feasibility. LifeStem is conservatively projecting $3,858,000 in revenues in the first twelve months of operation and $26,275,000 during the second twelve months of operation.
CalbaTech has generated revenues of $977,444 from operations for the nine months ended September 30, 2006, compared to $952,312 for the nine months ended September 30, 2005. For the three months ended September 30, 2006, CalbaTech has generated revenues of $322,322 as compared to $326,967 for the three months ended September 30, 2005
The Company realized Net Income for the three months ended September 30, 2006 of $616,459 as compared to a net loss of $300,073 for the same period in 2005
CalbaTech has continued to develop its intellectual property portfolio in the past year. This aims to protect novel concepts owned by the Company and developed by scientists associated with CalbaTech.
The first of these patent applications entitled "Device and methods for processing sample and detecting analytes at low concentration" is a provisional application 60/536,044 filed 01/13/04 by James Zoval, Ph.D. This was officially published by the USPTO 20th October Publication number US-2005-0233352-A1. This application describes a novel concept for the isolation and purification of DNA and other biological molecules. This concept fits within the overall molecular biology/media focus of CalbaTech's acquisition strategy and could become an important new product line.
The second patent application was provisional application entitled "Cardiac Stem Cell Delivery Apparatus" number 60/571,510 filed 06/10/2004 inventor Jason Van Tassel, M.D. This has been converted to full US application. This application is now entitled "Device and methods for treatment of necrotic tissue using" Serial No 11/149/960 filed June 10th 2005. This patent describes a modification of endoscope technology which will facilitate the targeted delivery of adult stem cells to specific tissues. This approach focusing on the process of adult stem cell delivery provides CalbaTech with an entry into the field of adult stem cells services.
Finally, CalbaTech has filed a third US provisional application entitled "methods for harvesting and storing autologous stem cells including blood derived hematopoeitic stem cell and adipose derived mesenchymal stem cells" CTEC provisional 00106 filed October 31st 2005. This describes specific methods and processes associated with adult stem cell storage which will be incorporated into LifeStem's business model.
quote:Originally posted by paulbest: Nice stock, I hope to pick some up today. Quest what do you think about another SC stock, CBAI?
actually CBAI is also a client of CLBE from what Paul in IR stated but they are 2 differant SC type companies....maybe the only relationship is based on the banking and cryogenics.
posted
The general laboratory supplies industry is $12 Billion to $14 Billion, and the molecular biology market to which the Company provides products and services for medical research and drug discovery on which billions of dollars are spent each year. Specifically, the molecular biology market is approximately $600 Million per year, and the RNAi market is estimated to be $328 Million by 2010
KD has moved into its new state-of-the-art ISO 9002 certified and FDA compliant facility featuring two class 100 clean rooms. It is believed that this new facility will provide additional growth opportunities to KD, not only in expanding product lines to existing customers but by providing contract manufacturing and leasing opportunities to pharmaceutical companies.Finally, KD will also experience growth and greater profitability due to a recent arrangement with a large company which produces much of the media used in KD's products. The OEM company will produce many of KD's media products at a cost much lower than KD's cost. This should allow KD to more aggressively sell these products, entering markets that were previously unavailable due to cost competitiveness, resulting in an increase in revenues and profitability.
FINANCIAL PROJECTIONS
The Reagents Division has two companies with combined 2005 revenues of approximately $1.225 Million in gross revenues. CalbaTech believes that combined revenues within the division will be $1.3 Million in 2006. Within three years, it is anticipated that revenues should grow to approximately $5 Million.
THE CELLULAR THERAPIES DIVISION
STRATEGY
The Cellular Therapies Division was created to house CalbaTech's emerging interests in cellular applications, particularly those relating to the use of adult stem cells. The Company believes this is an emerging market in which there are major opportunities for new entrants to establish new standards through novel stem cell research techniques and business models. The Company is positioning itself through strategic alliances to identify and take advantage of such opportunities as they emerge from the interaction between fundamental research and an evolving regulatory environment.
CalbaTech's wholly owned subsidiary LifeStem, Inc. was established take advantage of this rapidly expanding market. In addition to advancing its unique business model for stem cell banking and the provision of purified stem cells to researchers, CalbaTech has filed two patent application for intellectual property relating to (1) a device for the efficient and effective delivery of stem cells to diseased or dead areas of the heart (2) a method of collecting and storing two different types of stem cells in micro quantities for autologous use.
LIFESTEM, INC.
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 (Source DMD). This is projected due to the growth of new cellular therapeutics (both embryonic and adult stem cells), as well as clinical applications to compete with, or complement, existing pharma-based solutions. LifeStem's strategy is to leverage CalbaTech's infrastructure of companies to obtain a leadership position in the fast emerging stem cell collection arena and become the preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
LifeStem believes that over time it can position itself to become a leader of "Cellular Logistics" in this large new market. The company is focused on the following: (1) Providing a Stem Cell Microbank(TM) service to individuals; (2) Providing services and technologies to facilitate the efficient acquisition and delivery of purified adult stem cells to the research market and; (3) Developing delivery devices for clinical applications.
Stem Cell MicroBank(TM) Service
The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis may revolutionize the practice of medicine. The power and promise of stem cell therapies is just emerging, and the corresponding development of new clinical applications and therapies are expected to follow. LifeStem's Stem Cell Microbank(TM) Service focuses on refining existing collection processes that are gaining significant acceptance. The focus will be providing a stem cell collection process and storage service that maintains adult stem cells for future use and broadens the availability of a collection and storage service.
LifeStem believes that preserving one's healthy cells for future use for treatments, both known and those yet to be developed, is of utmost importance. The benefits of stem cell therapies have shown great success in the treatment of life threatening disease such as chronic heart failure and cancer. There is also significant promise that stem cells will play a prominent role in cures for other diseases such as Parkinsons, Alzheimers and Diabetes and others. According to the American Cancer Society, cancer is now the number one killer of Americans surpassing heart disease. This concept has great promise not only for the cure of such diseases but also in the prevention of disease though the periodic re-injection of one's own healthy stem cells in effect giving the immune system a "boost" of healthy stem cells.
posted
once this eventually breaks out above a dime it should gradually work its way into the mid .20's imo in the near term and once its sets a decent base its only a matter of time then!
posted
What I like about this company is that they are dealing with adult stem cells. No contoversy from religious groups. A low A/S of 94 mil is nice too.
Posts: 134 | From: PA | Registered: Mar 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Eek!]](eek.gif)
![[Wink]](wink.gif)
